Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary
embolism, is a common and potentially preventable cause of morbidity and mortality …

The recently introduced oral anticoagulants, dabigatran, rivaroxaban and apixaban, were
shown, in randomized controlled trials, to be at least as effective and safe as monitored …

Introduction: For over 60 years vitamin K antagonists have been the mainstay of oral therapy
for treatment and prevention of venous and arterial thromboembolic disease. The …

Venous thromboembolism (VTE) in acute medically ill patients is a leading cause of in-
hospital morbidity and mortality. A majority of these VTE events occur post-discharge, and …

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary
embolism (PE), remains a preventable cause of morbidity and mortality in hospitalized …

Introduction Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food and
Drug Administration for prophylaxis of venous thromboembolism in adult patients …

Background The APEX trial assessed the safety and efficacy of extended-duration
thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among …

Despite advances in diagnosis, prevention, and management, venous thromboembolism
(VTE) remains a common cause of morbidity and mortality. For decades, antithrombotic …

The prevention and treatment of venous thromboembolism (VTE) remains a clinical
challenge, primarily owing to drawbacks associated with the use of heparins and vitamin K …

Venous thromboembolism (VTE) results in significant morbidity and mortality. The
prevention and treatment of VTE is managed with anticoagulant therapy, historically …